{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 67,
  "pageCount": 366,
  "prevPage": 66,
  "nextPage": 68,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses historical publication data to cast doubt on the quality of the drug pitolisant by highlighting that the inventor prioritized other compounds.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/67",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-67",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "For example, a 2003 paper showed what was later renamed pitolisant alongside other drugs they chose instead, and then a 2008 paper stated their “lead structure” was one called FUB 637 – not pitolisant.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cce-109c18240469",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "image",
      "text": "Chemical structures of various H3 receptor antagonists",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f9a3567-a4ad-46c5-a732-c6c850f836ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "We find it revealing that pitolisant was synthesized as early as 2001, but Schwartz sidelined it for alternative H3 drug compounds like ciproxifan and many others, on which he published for years.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a6da3ba-b51d-4ef3-85ce-e08c88d43442",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.47,
        "x": 0.46,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "The present report provides an account of the synthesis and pharmacological evaluation of the new histamine H3 receptor ligands. Compound FUB 637 (Fig. 4), a potent histamine H3 receptor antagonist tested in vitro (hKi: 3.1 nM) and in vivo (ED50: 3.7 ± 1.0), was taken as a lead structure.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7714412a-2a6c-4575-9224-e1c1f05e0226",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "The present report provides an account of the synthesis and pharmacological evaluation of the new histamine H3 receptor ligands. Compound FUB 637 (Fig. 4), a potent histamine H3 receptor antagonist tested in vitro (hKi: 3.1 nM) and in vivo (ED50: 3.7 ± 1.0), was taken as a lead structure. — 2008 Schwartz paper",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cce-17d1f54c14df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://pubmed.ncbi.nlm.nih.gov/13679184/; https://pubmed.ncbi.nlm.nih.gov/18774720/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdd44daf-e081-4943-ae9e-3d951048c26e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 70,
      "from": 51,
      "beatId": "f412f440-0381-4eb7-b9f4-292dcebd62be",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": null,
      "evidence": "The document presents the conclusion that the company is a house of cards",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}